Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Primary Breast Cancer
Interventions: DRUG: Cabacitaxel|DRUG: Paclitaxel
Sponsor: German Breast Group